Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EU Court Cuts Perindopril Fines For Krka And Servier

Executive Summary

A ruling by the EU’s General Court has confirmed that agreements between Servier and several generics firms over perindopril constituted restrictions of competition. However, it has reduced by more than €100 million a fine on Servier and has eliminated entirely a fine on Krka.

You may also be interested in...

UK’s NHS Fails On £220m Perindopril Damages Claim

The UK’s National Health Service has been denied an attempt to pursue damages from Servier over high prices for perindopril stemming from the firm “practicing deceit on the European Patent Office and the English courts”.

Valsartan Helps Push Krka Profits Higher

Almost doubling its sales of valsartan in 2018 helped to push up Krka’s sales by 5% and its operating profit by 17%, the Slovenian company has reported.

Lupin's US Generics Turn Corner, Spotlight On Upcoming Launches

A recovery in the US, aided by abating pricing pressure and portfolio exits by some large players, augurs well for Indian firm Lupin, but impending new launches including levothyroxine will need to deliver to sustain US momentum.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts